(Q38720829)

5 September 2017

1 reference

title

Current advances in targeted therapies for metastatic gastric cancer: improving patient care (English)

1 reference

5 September 2017

author name string

Pedro Nazareth Aguiar

1

1 reference

5 September 2017

Thiago Pimentel Muniz

2

1 reference

5 September 2017

Raelson Rodrigues Miranda

3

1 reference

5 September 2017

Hakaru Tadokoro

4

1 reference

5 September 2017

Nora Manoukian Forones

5

1 reference

5 September 2017

Ines-de-Paula Monteiro

6

1 reference

5 September 2017

Pedro Castelo-Branco

7

1 reference

5 September 2017

Yelena Y Janjigian

8

1 reference

5 September 2017

Ramon Andrade de Mello

9

1 reference

5 September 2017

language of work or name

English

0 references

publication date

3 February 2016

1 reference

5 September 2017

1 reference

5 September 2017

volume

12

1 reference

5 September 2017

issue

6

1 reference

5 September 2017

page(s)

839-854

1 reference

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Clinical management of advanced gastric cancer: the role of new molecular drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Molecular classification of gastric cancer: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Comparisons of Gastric Cancer Treatments: East vs. West

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

The ErbB/HER family of protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Targeted therapies in gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.348

21 January 2018

Identifiers

DOI

10.2217/FON.15.348

1 reference

5 September 2017

1 reference